patient

Chronic Kidney Disease and PNH

Thumbnail for video Watch Now

Topic(s)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Presenter(s)
Ramy M. Hanna, MD, FASN, FACP
Dr. Ramy Hanna is an Assistant Clinical Professor of Medicine and Nephrology at the University of California Irvine UCI-Health. He is a clinician-educator who works at the intersection of patient education and research, participating in ongoing research into diseases of the…

Living with PNH: A Patient Panel Discussion

Thumbnail for video Watch Now

Topic(s)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Join AAMDSIF's Leigh Clark for a panel discussion with two longer-term PNH patients, Marlena Connor and Jessi Hackney. Marlena and Jessi talk about their experiences as patients, what they wish they'd knowns when they were being diagnosed, what resources are important to them and…

A Candid Conversation with Caregivers

Thumbnail for video Watch Now

Topic(s)
Living Well with Bone Marrow Failure
Managing Your Treatment
Presenter(s)
Leigh Clark
This webinar focuses on the experience of caregivers who have been with their loved ones through the diagnosis, treatment and survivorship stages of bone marrow failure disease. We are grateful to our caregivers for sharing their time with us.

Real-World Treatment Patterns, FLT3 Testing, and Outcomes in AML

Original Publication Date
Article Source
External Web Content
Amer Zeidan, MBBS, MHS, Yale University School of Medicine and Yale Cancer Center, New Haven, Connecticut, discusses updated results from an ongoing retrospective study examining FLT3 testing trends, treatment patterns, and overall survival in patients with relapsed/refractory…

Outcomes of Adding a Fourth Chemotherapy Course in AML

Original Publication Date
Article Source
External Web Content
Administering 2 additional courses of chemotherapy with high-dose cytarabine (Ara-C) after 2 courses of induction therapy improved relapse rates but did not improve overall survival for patients with acute myeloid leukemia (AML), according to research in the Journal of Clinical…

Precision Medicine Approach Deemed Safe, Feasible for Older Patients With Untreated AML

Original Publication Date
Article Source
External Web Content
A precision medicine treatment approach that incorporates genomic data into treatment decisions appears to be feasible in older patients with untreated acute myeloid leukemia (AML), according to a study published in Nature Medicine. Investigators also found that delaying…

Pegcetacoplan Bests Eculizumab for PNH Patients

Original Publication Date
Article Source
External Web Content
Results from the phase III PEGASUS trial suggest that the targeted C3 inhibitor pegcetacoplan improved hemoglobin levels better than eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) who were still anemic despite at least three months of eculizumab therapy…

Overcoming Clinical Challenges Associated With TP53-Mutant MDS, AML

Original Publication Date
Article Source
External Web Content
TP53-mutant myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) represent a molecularly distinct, poor-risk patient subgroup frequently associated with complex karyotypes, high propensity for relapse, and inferior overall survival. Across TP53-altered MDS and AML…
Subscribe to patient

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.